Fortrea Holdings Inc.
FTREHealthcare|Biotechnology|US
$21.96
+1.50 (+7.33%)
Cash / Share
$2.31
Clinical Trials (35)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06651970 Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment | P4 | Recruiting | 60 | RCT, Open-label | Acalabrutinib |
| NCT06933472 A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China | Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis | P3 | Recruiting | 264 | RCT, Double-blind | AP301, AP301 Low Dose |
| NCT06473779 Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | Severe Asthma | P3 | Active | 310 | RCT, Open-label | — |
| NCT05693129 Pediatric Patients Aged 1 to 6 Years With APDS | APDS | P3 | Active | 16 | Open-label | Leniolisib |
| NCT06223958 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration | P3 | Active | 344 | RCT, Double-blind | OTX-TKI (axitinib implant), Aflibercept |
| NCT06495918 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | P3 | Active | 825 | RCT, Double-blind | OTX-TKI, Aflibercept, Aflibercept |
| NCT06706817 A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | Chronic Rhinosinusitis With Nasal Polyps | P3 | Active | 181 | Open-label | — |
| NCT05438407 Pediatric Patients Aged 4 to 11 Years With APDS | APDS | P3 | Active | 15 | Open-label | Leniolisib |
| NCT05933057 Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | P3 | Recruiting | 138 | RCT, Double-blind | Givinostat, Placebo |
| NCT07516132 Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study | Neovascular Age-Related Macular Degeneration (nAMD) | P3 | Recruiting | 850 | Open-label | OTX-TKI |
| NCT07219238 Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | Colorectal Cancer, Gastric Cancers | P2P3 | Recruiting | 175 | Open-label | GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) |
| NCT07109219 Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia (B-ALL) | P1P2 | Recruiting | 83 | Open-label | — |
| NCT07244705 A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC | Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic | P1P2 | Recruiting | 66 | RCT, Open-label | ABT-301, Tislelizumab, Bevacizumab (Avastin) |
| NCT06769633 Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old | Duchenne Muscular Dystrophy | P2 | Recruiting | 18 | Open-label | Givinostat Hydrochloride, Givinostat Hydrochloride - Cohort 2 |
| NCT07820891 A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395 | Healthy Adult Participants | P1 | Recruiting | 24 | Open-label | BGB-43395, Midazolam, Celecoxib, Dabigatran etexilate, Rosuvastatin |
| NCT06713369 AZD5305 hADME in Patients With Advanced Solid Malignancies | Locally Advanced or Metastatic Solid Tumor | P1 | Recruiting | 8 | Open-label | Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose) |
| NCT06916806 A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies | P1 | Recruiting | 72 | Open-label | AZD5492 |
| NCT06083012 Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation | Atrial Fibrillation, Atrial Arrhythmia | Active | 186 | — | — | |
| NCT06398743 First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer | Colorectal Cancer | Active | 416 | — | — | |
| NCT07017933 Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes | Renal Impairment After Cardiac Surgery, Renal Impairment | N/A | Recruiting | 124 | RCT, Open-label | — |
| NCT06563102 Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma | Mild Asthma | P4 | Completed | 101 | RCT, Double-blind | — |
| NCT03748134 Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | Esophageal Squamous Cell Carcinoma | P3 | Completed | 746 | RCT, Double-blind | Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo |
| NCT07850453 Vortosiran for VTE Prevention | Venous Thromboembolism (VTE), Cancer | P2 | Not Yet Recruiting | 150 | RCT, Double-blind | Vortosiran, Placebo |
| NCT06692764 A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure | Atherosclerotic Cardiovascular Disease | P2 | Completed | 202 | RCT, Double-blind | Placebo, AZD0780 |
| NCT04817670 Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease | Sickle Cell Disease | P2 | Completed | 25 | RCT, Double-blind | VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID |
| NCT05636852 Altropane Dose for Imaging Patients With Suspected Parkinson's Disease | Parkinson Disease, Movement Disorders | P2 | Terminated | 15 | Open-label | Altropane (123I) Injection |
| NCT07884136 RBD1119 in Coronary Artery Disease (CAD) | Stable Coronary Artery Disease | P2 | Not Yet Recruiting | 200 | RCT, Double-blind | RBD1119, Placebo |
| NCT06432647 A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105 | Healthy Volunteers | P1 | Completed | 80 | RCT, Double-blind | ATH-1105, Placebo |
| NCT06813781 Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004 | Hepatic Impairment | P1 | Completed | 33 | Open-label | AZD5004 |
| NCT07754331 Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin | Kidney Failure | P1 | Completed | 10 | RCT, Open-label | Balcinrenone/dapagliflozin |
| NCT06398730 A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 22 | Open-label | GEH200520 Injection and GEH200521 (18F) Injection |
| NCT07093398 A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants | Healthy Adult Volunteers | P1 | Completed | 26 | RCT, Open-label | D3S-001 |
| NCT04702451 Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation | Atrial Fibrillation | N/A | Completed | 377 | RCT, Double-blind | — |
| NCT04498026 Adherus™ Dural Sealant in Spinal Procedures | Spinal Duraplasty | N/A | Completed | 94 | RCT, Single-blind | — |
| NCT05981495 Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection Kit for the Diagnosis of Tuberculosis Disease | Tuberculosis, Pulmonary, Tuberculosis, Extrapulmonary | Unknown | 460 | — | — |